.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,213,804

« Back to Dashboard

Claims for Patent: 5,213,804

Title: Solid tumor treatment method and composition
Abstract:A liposome composition for localizing an anti-tumor compound to a solid tumor via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.12 microns. After intravenous administration, the liposomes are taken up by the tumor within 24-48 hours, for site-specific release of entrapped compound into the tumor. In one composition for use in treating a solid tumor, the compound is an anthracycline antibiotic drug which is entrapped in the liposomes at a concentration of greater than about 50 .mu.g agent/.mu.mole liposome lipid. The method results in regression of solid colon and breast carcinomas which are refractory to anthracycline antibiotic drugs administered in free form or entrapped in conventional liposomes.
Inventor(s): Martin; Francis J. (San Francisco, CA), Woodle; Martin C. (Menlo Park, CA), Redemann; Carl (Walnut Creek, CA), Yau-Young; Annie (Palo Alto, CA)
Assignee: Liposome Technology, Inc. (Menlo Park, CA)
Application Number:07/642,321
Patent Claims: 1. A liposome composition for use in localizing a compound in a solid tumor via the bloodstream, by liposome extravasation into the tumor, comprising

liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of an amphipathic vesicle-forming lipid derivatized with a hydrophilic polymer selected from the group consisting of polyethyleneglycol, polylactic acid, polyglycolic acid and polylactic acid/polyglycolic acid copolymers, and (ii) having a selected mean particle diameter in the size range between about 0.07 to 0.12 microns, and

the compound in liposome-entrapped form,

and characterized by a liposome blood lifetime, 24 hours after intravenous injection, that is several times greater than the blood lifetime of liposomes in the absence of the derivatized lipid.

2. The composition of claim 1, wherein the hydrophilic polymer is polyethyleneglycol having a molecular weight between about 1,000-5,000 daltons.

3. The composition of claim 2, wherein the hydrophilic polymer is selected from the group of polylactic acid, polyglycolic acid, and copolymers thereof.

4. The composition of claim 1, wherein the compound is an anti-tumor agent, and at least about 80% of the compound is in liposome-entrapped form.

5. The composition of claim 4, wherein the anti-tumor agent is an anthracycline antibiotic, and the concentration of compound which is entrapped in the liposomes is greater than 50 .mu.g compound/.mu.mole liposome lipid.

6. The composition of claim 4, wherein the anthracycline is selected from the group consisting of doxorubicin, epirubicin, and daunorubicin, including pharmacologically acceptable salts and acids thereof.

7. A liposome composition for use in localizing an anthracycline anti-tumor drug in a solid tumor via the bloodstream by liposome extravasation into the tumor, comprising,

liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of an amphipathic vesicle-forming lipid derivatized with polyethyleneglycol, and (ii) having an average size in a selected size range between about 0.07 to 0.12 microns, and

the drug, at least about 80% in liposome-entrapped form, and having a concentration in the liposomes greater than 50 .mu.g agent/.mu.mole liposome lipid,

and characterized by a liposome blood lifetime, 24 hours after intravenous injection, that is several times greater than the blood lifetime of liposomes in the absence of the derivatized lipid.

8. A method of preparing an agent for localization in a solid tumor by extravasation of liposomes containing the agent into the solid tumor, when the agent is administered by IV injection, comprising

entrapping the agent in liposomes which are characterized by:

(a) a lipid composition which includes between 1-20 mole percent of an amphipathic vesicle-forming lipid derivatized with a hydrophilicpolymer selected from the group consisting of polyethyleneglycol, polylactic acid, polyglycolic acid and polyactic acid/polyglycolic acid copolymers,

(b) an average liposome size in a selected size range between about 0.07-0.12 microns; and

(c) a liposome blood lifetime 24 hours after intravenous injection, that is several times greater than the blood lifetime of liposomes in the absence of the derivatized lipid.

9. The method of claim 8, wherein the agent is an anthracycline antibiotic drug, and said entrapping includes loading the agent into preformed liposomes by remote loading across an ion or pH gradient, to a final concentration of lipisome-entrapped material of greater than about 50 .mu.g agent/.mu.mole liposome lipid.

10. The method of claim 9, wherein the drug is selected from the group consisting of doxorubicin, epirubicin, and daunorubicin, including pharmacologically acceptable salts and acids thereof.

11. A method of localizing a compound in a solid tumor in a subject by extravasation of liposomes containing the agent into the solid tumor comprising,

preparing a composition of liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of an amphipathic vesicle-forming lipid derivatized with a hydrophilic polymer selected from the group consisting of polyethyleneglycol, polylactic acid, polyglycolic acid and polylactic acid/polyglycolic acid copolymers, said liposomes having a blood lifetime, as measured by the percent of a liposome marker present in the blood 24 hours after intravenous administration, which is several times greater than that of liposomes in absence of the derivatized lipids, (ii) having an average size in a selected size range between about 0.07-0.12 microns, and (iii) containing the compound in liposome-entrapped form,

injecting the composition intravenously in the subject in an amount effective to localize a therapeutically effective quantity of the agent in the solid tumor, and

by said injecting, achieving a localization of the liposomes in the solid tumor, 48 hours after intravenous administration, that is substantially greater than that of liposomes in the absence of the derivatized lipid.

12. The method of claim 11, wherein the hydrophilic polymer is polyethyleneglycol having a molecular weight between about 1,000-5,000 daltons.

13. A method of treating breast or colon carcinoma in a subject with an anthracycline antibiotic drug, comprising

entrapping the drug in liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of an amphipathic vesicle-forming lipid derivatized with a hydrophilic polymer selected from the group consisting of polyethyleneglycol, polylactic acid, polyglycolic acid and polylactic acid/polyglycolic acid copolymers, said liposomes having a blood lifetime, as measured by the percent of a liposome marker present in the blood 24 hours after intravenous administration, which is several times greater than that of liposomes in absence of the derivatized lipids, and (ii) having an average size in a selected size range between about 0.07-0.12 microns at a concentration of entrapped drug of greater than about 50 .mu.g drug/.mu.mole liposome lipid, with at least about 80% of the drug entrapped in the liposomes, and

injecting the composition intravenously in the subject in an amount effective to localize a therapeutically effective quantity of the agent in the carcinoma.

14. The method of claim 13, wherein the hydrophilic polymer is polyethyleneglycol having a molecular weight between about 1,000-5,000 daltons, and the agent is selected from the group consisting of doxorubicin, epirubicin, and daunorubicin, including a pharmacologically acceptable salts and acids thereof.

15. The composition of claim 7, wherein the drug is selected from the group consisting of doxorubicin, epirubicin, and daunorubicin, including pharmacologically acceptable salts and acids thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc